TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: To Investigate the PRevention of OM-85 on Bronchiectasis Exacerbation (iPROBE): a Multicenter, Randomised, Double-dummy, Placebo-controlled Clinical Trial in Chinese Patients
Brief Summary: Non-cystic fibrosis bronchiectasis is characterized by irreversible dilatation of the medium-sized bronchi as a result of airway injury due to recurrent or chronic inflammation and infection. Bronchiectasis airways are often colonized with bacterial species. Infections of the airways are thought to play an important role in bronchiectasis exacerbation. The non-specific prevention of recurrent airway infections by immunostimulating agents has gained growing scientific interest. OM-85, consisting extracts of eight kinds of bacteria important in respiratory infections, has shown the benefit for significantly reducing the incidence of exacerbations of chronic obstructive pulmonary disease (COPD). The purpose of this study is to investigate the PReventive effect of OM-85 on Bronchiectasis Exacerbation in Chinese patients (iPROBE).

This study is designed as a prospective randomised double-blind placebo-controlled multi-centred trial.


Options:
A: Arm Label: Acapella Physiotherapy; Type: EXPERIMENTAL; Interventions: Device: Acapella Physiotherapy | Arm Label: No physiotherapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Acapella Physiotherapy; Assigned to Arm(s): Acapella Physiotherapy
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gentamicin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Gentamicin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): 2
C: Arm Label: OM-85; Type: EXPERIMENTAL; Interventions: Drug: OM-85 BV | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: OM-85 BV | Intervention Type: DRUG; Name: OM-85 BV; Assigned to Arm(s): OM-85, Placebo
D: Arm Label: Azithromycin treatment 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin treatment 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: To Investigate the PRevention of OM-85 on Bronchiectasis Exacerbation (iPROBE): a Multicenter, Randomised, Double-dummy, Placebo-controlled Clinical Trial in Chinese Patients
Brief Summary: Non-cystic fibrosis bronchiectasis is characterized by irreversible dilatation of the medium-sized bronchi as a result of airway injury due to recurrent or chronic inflammation and infection. Bronchiectasis airways are often colonized with bacterial species. Infections of the airways are thought to play an important role in bronchiectasis exacerbation. The non-specific prevention of recurrent airway infections by immunostimulating agents has gained growing scientific interest. OM-85, consisting extracts of eight kinds of bacteria important in respiratory infections, has shown the benefit for significantly reducing the incidence of exacerbations of chronic obstructive pulmonary disease (COPD). The purpose of this study is to investigate the PReventive effect of OM-85 on Bronchiectasis Exacerbation in Chinese patients (iPROBE).

This study is designed as a prospective randomised double-blind placebo-controlled multi-centred trial.


Options:
A: Arm Label: NPPV group; Type: EXPERIMENTAL; Interventions: Device: ventilators designed for non invasive ventilation | Arm Label: control gorup; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: ventilators designed for non invasive ventilation; Assigned to Arm(s): NPPV group
B: Arm Label: Smokers without COPD; Type: N/A; Interventions: N/A | Arm Label: Severe COPD; Type: N/A; Interventions: N/A | Arm Label: Mild/Moderate COPD; Type: N/A; Interventions: N/A | Arm Label: Non-smokers; Type: N/A; Interventions: N/A
C: Arm Label: OM-85; Type: EXPERIMENTAL; Interventions: Drug: OM-85 BV | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: OM-85 BV | Intervention Type: DRUG; Name: OM-85 BV; Assigned to Arm(s): OM-85, Placebo
D: Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Educational Intervention to Reduce Outpatient Inappropriate Transthoracic Echocardiograms Ordered by Attending Physicians
Brief Summary: The utilization of transthoracic echocardiography in the United States has been increasing. This has resulted in increased costs to the healthcare system. In an effort to curb excessive utilization of this technology, the American College of Cardiology created Appropriate Use Criteria to help guide clinicians to use this diagnostic imaging modality more appropriately. The investigators previously showed that an educational intervention can reduce the rate of inappropriate echocardiograms ordered by physicians-in-training. It is unknown if such an intervention would be successful in attending, staff level of physicians. The investigators hypothesize that an educational and feedback intervention will reduce the rate of inappropriate outpatient transthoracic echocardiograms ordered by staff cardiologists and internal medicine physicians.


Options:
A: Arm Label: Training course for practice nurses in autonomy support; Type: EXPERIMENTAL; Interventions: Behavioral: Training course for practice nurses in autonomy support | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Training course for practice nurses in autonomy support; Assigned to Arm(s): Training course for practice nurses in autonomy support
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Provider Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: RDTs & Provider Training on Malaria Diagnosis and Treatment | Arm Label: Extended intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: RDTs & Provider Training on Malaria Diagnosis and Treatment, Behavioral: Extended provider training (Cameroon only), Behavioral: School based malaria education (Nigeria only) | Intervention Type: BEHAVIORAL; Name: RDTs & Provider Training on Malaria Diagnosis and Treatment; Assigned to Arm(s): Extended intervention, Provider Intervention | Intervention Type: BEHAVIORAL; Name: Extended provider training (Cameroon only); Assigned to Arm(s): Extended intervention | Intervention Type: BEHAVIORAL; Name: School based malaria education (Nigeria only); Assigned to Arm(s): Extended intervention
C: Arm Label: Educational Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Educational Intervention | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Educational Intervention; Assigned to Arm(s): Educational Intervention
D: Arm Label: Interactive educational intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Education | Arm Label: Didactic educational intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Education | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): Didactic educational intervention, Interactive educational intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Long-term Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Brief Summary: This study is a multicenter, randomized study in subjects with high cholesterol receiving highly effective statins to assess the efficacy, safety and tolerability of Bococizumab (PF-04950615;RN316) to lower LDL-C.


Options:
A: Arm Label: Bococizumab (PF-04950615; RN316); Type: EXPERIMENTAL; Interventions: Drug: Bococizumab (PF-04950615; RN316) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bococizumab (PF-04950615; RN316); Assigned to Arm(s): Bococizumab (PF-04950615; RN316) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for alirocumab), Drug: Lipid-Modifying Therapy (LMT) | Arm Label: Alirocumab; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Lipid-Modifying Therapy (LMT) | Intervention Type: DRUG; Name: Placebo (for alirocumab); Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab | Intervention Type: DRUG; Name: Lipid-Modifying Therapy (LMT); Assigned to Arm(s): Alirocumab, Placebo
C: Arm Label: Bococizumab 150mg; Type: EXPERIMENTAL; Interventions: Biological: Bococizumab 150mg | Arm Label: Bococizumab 75mg; Type: EXPERIMENTAL; Interventions: Biological: Bococizumab 75mg | Arm Label: Bococizumab 150mg placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Bococizumab 150mg placebo | Arm Label: Bococizumab 75mg placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Bococizumab 75mg placebo | Intervention Type: BIOLOGICAL; Name: Bococizumab 150mg; Assigned to Arm(s): Bococizumab 150mg | Intervention Type: BIOLOGICAL; Name: Bococizumab 75mg; Assigned to Arm(s): Bococizumab 75mg | Intervention Type: BIOLOGICAL; Name: Bococizumab 150mg placebo; Assigned to Arm(s): Bococizumab 150mg placebo | Intervention Type: BIOLOGICAL; Name: Bococizumab 75mg placebo; Assigned to Arm(s): Bococizumab 75mg placebo
D: Arm Label: Q28d Dosing Arm; Type: EXPERIMENTAL; Interventions: Drug: PBO, Drug: 200mg PF-04950615 (RN316), Drug: 300mg PF-04950615 (RN316) | Arm Label: Q14d Dosing Arm; Type: EXPERIMENTAL; Interventions: Drug: PBO, Drug: PF-04950615 | Intervention Type: DRUG; Name: PBO; Assigned to Arm(s): Q28d Dosing Arm | Intervention Type: DRUG; Name: 200mg PF-04950615 (RN316); Assigned to Arm(s): Q28d Dosing Arm | Intervention Type: DRUG; Name: 300mg PF-04950615 (RN316); Assigned to Arm(s): Q28d Dosing Arm | Intervention Type: DRUG; Name: PBO; Assigned to Arm(s): Q14d Dosing Arm | Intervention Type: DRUG; Name: PF-04950615; Assigned to Arm(s): Q14d Dosing Arm | Intervention Type: DRUG; Name: PF-04950615; Assigned to Arm(s): Q14d Dosing Arm | Intervention Type: DRUG; Name: PF-04950615; Assigned to Arm(s): Q14d Dosing Arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Long-term Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Brief Summary: This study is a multicenter, randomized study in subjects with high cholesterol receiving highly effective statins to assess the efficacy, safety and tolerability of Bococizumab (PF-04950615;RN316) to lower LDL-C.


Options:
A: Arm Label: Placebo Q2W; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for alirocumab), Drug: Lipid-Modifying Therapy (LMT) | Arm Label: Alirocumab; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Lipid-Modifying Therapy (LMT) | Intervention Type: DRUG; Name: Placebo (for alirocumab); Assigned to Arm(s): Placebo Q2W | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab | Intervention Type: DRUG; Name: Lipid-Modifying Therapy (LMT); Assigned to Arm(s): Alirocumab, Placebo Q2W
B: Arm Label: Evolocumab; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab, Drug: Atorvastatin, Drug: Ezetimibe, Other: Diet Only | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Drug: Atorvastatin, Drug: Ezetimibe, Other: Diet Only | Intervention Type: BIOLOGICAL; Name: Evolocumab; Assigned to Arm(s): Evolocumab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Evolocumab, Placebo | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Evolocumab, Placebo | Intervention Type: OTHER; Name: Diet Only; Assigned to Arm(s): Evolocumab, Placebo
C: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: Cohort 3; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: Cohort 4; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Intervention Type: DRUG; Name: REGN727; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3, Cohort 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3, Cohort 4
D: Arm Label: Bococizumab (PF-04950615; RN316); Type: EXPERIMENTAL; Interventions: Drug: Bococizumab (PF-04950615; RN316) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bococizumab (PF-04950615; RN316); Assigned to Arm(s): Bococizumab (PF-04950615; RN316) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia
Brief Summary: This is a multicenter, randomized study in subjects with heterozygous familial hypercholesterolemia receiving highly effective statins to assess the safety, efficacy and tolerability of Bococizumab (PF-04950615; RN316) to lower LDL-C.


Options:
A: Arm Label: Alirocumab 75 /up to 150 mg Q2W; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Placebo (for ezetimibe), Drug: Lipid Modifying Therapy (LMT) | Arm Label: Ezetimibe 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo (for alirocumab), Drug: Ezetimibe, Drug: Lipid Modifying Therapy (LMT) | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 75 /up to 150 mg Q2W | Intervention Type: DRUG; Name: Placebo (for alirocumab); Assigned to Arm(s): Ezetimibe 10 mg | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Ezetimibe 10 mg | Intervention Type: DRUG; Name: Placebo (for ezetimibe); Assigned to Arm(s): Alirocumab 75 /up to 150 mg Q2W | Intervention Type: DRUG; Name: Lipid Modifying Therapy (LMT); Assigned to Arm(s): Alirocumab 75 /up to 150 mg Q2W, Ezetimibe 10 mg
B: Arm Label: Bococizumab (PF-04950615;RN316); Type: EXPERIMENTAL; Interventions: Drug: Bococizumab (PF-04950615;RN316) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bococizumab (PF-04950615;RN316); Assigned to Arm(s): Bococizumab (PF-04950615;RN316) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo Q2W; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for alirocumab), Drug: Lipid-Modifying Therapy (LMT) | Arm Label: Alirocumab; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Lipid-Modifying Therapy (LMT) | Intervention Type: DRUG; Name: Placebo (for alirocumab); Assigned to Arm(s): Placebo Q2W | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab | Intervention Type: DRUG; Name: Lipid-Modifying Therapy (LMT); Assigned to Arm(s): Alirocumab, Placebo Q2W
D: Arm Label: Q28d Dosing Arm; Type: EXPERIMENTAL; Interventions: Drug: PBO, Drug: 200mg PF-04950615 (RN316), Drug: 300mg PF-04950615 (RN316) | Arm Label: Q14d Dosing Arm; Type: EXPERIMENTAL; Interventions: Drug: PBO, Drug: PF-04950615 | Intervention Type: DRUG; Name: PBO; Assigned to Arm(s): Q28d Dosing Arm | Intervention Type: DRUG; Name: 200mg PF-04950615 (RN316); Assigned to Arm(s): Q28d Dosing Arm | Intervention Type: DRUG; Name: 300mg PF-04950615 (RN316); Assigned to Arm(s): Q28d Dosing Arm | Intervention Type: DRUG; Name: PBO; Assigned to Arm(s): Q14d Dosing Arm | Intervention Type: DRUG; Name: PF-04950615; Assigned to Arm(s): Q14d Dosing Arm | Intervention Type: DRUG; Name: PF-04950615; Assigned to Arm(s): Q14d Dosing Arm | Intervention Type: DRUG; Name: PF-04950615; Assigned to Arm(s): Q14d Dosing Arm

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia
Brief Summary: This is a multicenter, randomized study in subjects with heterozygous familial hypercholesterolemia receiving highly effective statins to assess the safety, efficacy and tolerability of Bococizumab (PF-04950615; RN316) to lower LDL-C.


Options:
A: Arm Label: Bococizumab 150mg; Type: EXPERIMENTAL; Interventions: Biological: Bococizumab 150mg | Arm Label: Bococizumab 75mg; Type: EXPERIMENTAL; Interventions: Biological: Bococizumab 75mg | Arm Label: Bococizumab 150mg placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Bococizumab 150mg placebo | Arm Label: Bococizumab 75mg placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Bococizumab 75mg placebo | Intervention Type: BIOLOGICAL; Name: Bococizumab 150mg; Assigned to Arm(s): Bococizumab 150mg | Intervention Type: BIOLOGICAL; Name: Bococizumab 75mg; Assigned to Arm(s): Bococizumab 75mg | Intervention Type: BIOLOGICAL; Name: Bococizumab 150mg placebo; Assigned to Arm(s): Bococizumab 150mg placebo | Intervention Type: BIOLOGICAL; Name: Bococizumab 75mg placebo; Assigned to Arm(s): Bococizumab 75mg placebo
B: Arm Label: Bococizumab (PF-04950615;RN316); Type: EXPERIMENTAL; Interventions: Drug: Bococizumab (PF-04950615;RN316) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bococizumab (PF-04950615;RN316); Assigned to Arm(s): Bococizumab (PF-04950615;RN316) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: bococizumab (PF-04950615); Type: EXPERIMENTAL; Interventions: Drug: bococizumab (PF-04950615) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: bococizumab (PF-04950615); Assigned to Arm(s): bococizumab (PF-04950615) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Bococizumab (PF-04950615; RN316); Type: EXPERIMENTAL; Interventions: Drug: Bococizumab (PF-04950615; RN316) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bococizumab (PF-04950615; RN316); Assigned to Arm(s): Bococizumab (PF-04950615; RN316) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Shared Decision Making in the Emergency Department: The Chest Pain Choice Trial
Brief Summary: Our long-term goal is to promote evidence-based patient-centered evaluation in the acute setting to more closely tailor testing to disease risk. To compare the use of risk stratification tools with usual clinical approaches to treatment selection or administration, we propose the following:

1. Test if Chest Pain Choice safely improves validated patient-centered outcome measures in a pragmatic parallel patient randomized trial.

   Hypothesis: The intervention will significantly increase patient knowledge, engagement, and satisfaction with no increase in adverse events.
2. Test if the decision aid has an effect on healthcare utilization within 30 days after enrollment.

Hypothesis: The intervention will significantly reduce the rate of hospital admission, rate of cardiac testing, and total healthcare utilization.


Options:
A: Arm Label: Chest Pain Choice Decision Aid; Type: ACTIVE_COMPARATOR; Interventions: Other: Chest Pain Choice Decision Aid | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Chest Pain Choice Decision Aid; Assigned to Arm(s): Chest Pain Choice Decision Aid
B: Intervention Type: DEVICE; Name: Decision Aid Statin Choice; Assigned to Arm(s): N/A
C: Arm Label: Usual Support Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual-Support | Arm Label: Enhanced Support Group; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Support | Intervention Type: BEHAVIORAL; Name: Enhanced Support; Assigned to Arm(s): Enhanced Support Group | Intervention Type: BEHAVIORAL; Name: Usual-Support; Assigned to Arm(s): Usual Support Group
D: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: CHOICE decision aid | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: YourMeds patient education program | Intervention Type: BEHAVIORAL; Name: CHOICE decision aid; Assigned to Arm(s): Intervention group | Intervention Type: BEHAVIORAL; Name: YourMeds patient education program; Assigned to Arm(s): Placebo group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Shared Decision Making in the Emergency Department: The Chest Pain Choice Trial
Brief Summary: Our long-term goal is to promote evidence-based patient-centered evaluation in the acute setting to more closely tailor testing to disease risk. To compare the use of risk stratification tools with usual clinical approaches to treatment selection or administration, we propose the following:

1. Test if Chest Pain Choice safely improves validated patient-centered outcome measures in a pragmatic parallel patient randomized trial.

   Hypothesis: The intervention will significantly increase patient knowledge, engagement, and satisfaction with no increase in adverse events.
2. Test if the decision aid has an effect on healthcare utilization within 30 days after enrollment.

Hypothesis: The intervention will significantly reduce the rate of hospital admission, rate of cardiac testing, and total healthcare utilization.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: You Decide | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Reducing Your Risks in the Crash | Intervention Type: OTHER; Name: You Decide; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Reducing Your Risks in the Crash; Assigned to Arm(s): 2
B: Arm Label: Chest Pain Choice Decision Aid; Type: ACTIVE_COMPARATOR; Interventions: Other: Chest Pain Choice Decision Aid | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Chest Pain Choice Decision Aid; Assigned to Arm(s): Chest Pain Choice Decision Aid
C: Arm Label: Decision Aid; Type: EXPERIMENTAL; Interventions: Other: Decision Aid | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Decision Aid; Assigned to Arm(s): Decision Aid
D: Arm Label: Depression Self-care Intervention (SCI); Type: EXPERIMENTAL; Interventions: Behavioral: Depression self-care | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Depression self-care; Assigned to Arm(s): Depression Self-care Intervention (SCI)

Answer: B